We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-5.18%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$2.76B
AUM Growth
-$525M
Cap. Flow
-$439M
Cap. Flow %
-15.9%
Top 10 Hldgs %
38.29%
Holding
343
New
69
Increased
54
Reduced
100
Closed
111

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$17.9M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$17.3M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$14.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14M
5
CUTR
Cutera, Inc.
CUTR
+$12.7M

Top Sells

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$24.7M
2
MAPS
WM TECHNOLOGY INC A
MAPS
+$23.4M
3
LIVN icon
LivaNova
LIVN
+$20.2M
4
GKOS icon
Glaukos
GKOS
+$17.5M
5
COO icon
Cooper Companies
COO
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 29.75%
2 Consumer Staples 0.58%
3 Financials 0.5%
4 Consumer Discretionary 0.42%
5 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TALKW
226
DELISTED
Talkspace Inc Warrant
TALKW
$99K ﹤0.01%
427,194
-13,261
-3% -$6.41K
EFTRW
227
DELISTED
eFFECTOR Therapeutics, Inc. Warrant
EFTRW
$88K ﹤0.01%
+100,541
New +$126K
RCOR.WS
228
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$86K ﹤0.01%
150,632
– –
MAPSW
229
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$67K ﹤0.01%
50,000
– –
ABUS icon
230
Arbutus Biopharma
ABUS
$907M
– –
-100,000
Closed -$429K
ADPT icon
231
Adaptive Biotechnologies
ADPT
$4.02B
– –
-255,916
Closed -$7.84M
ALT icon
232
PUT
Altimmune
ALT
$570M
– –
-39,000
Closed -$441K
AMGN icon
233
CALL
Amgen
AMGN
$225B
– –
-50,000
Closed -$10.6M
AMN icon
234
AMN Healthcare
AMN
$1.26B
– –
-80,000
Closed -$8.88M
APLS
235
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-259,100
Closed -$8.54M
ATAI icon
236
PUT
AtaiBeckley Inc
ATAI
$2.68B
– –
-651,500
Closed -$9.64M
AVDL
237
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-192,000
Closed -$1.88M
AZN icon
238
AstraZeneca
AZN
$246B
– –
-25,000
Closed -$3M
BAX icon
239
CALL
Baxter International
BAX
$13.9B
– –
-250,000
Closed -$20.1M
BCLI
240
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-6,493
Closed -$321K
BCLI
241
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-7,122
Closed -$353K
BHC icon
242
Bausch Health
BHC
$2.32B
– –
-100,000
Closed -$2.68M
BNGO icon
243
Bionano Genomics
BNGO
$13.8M
– –
-833
Closed -$2.75M
BYSI icon
244
BeyondSpring
BYSI
$30.5M
– –
-20,100
Closed -$317K
BYSI icon
245
PUT
BeyondSpring
BYSI
$30.5M
– –
-16,900
Closed -$266K
CGEM icon
246
Cullinan Oncology
CGEM
$1.26B
– –
-81,418
Closed -$1.84M
CLSD
247
CALL
DELISTED
Clearside Biomedical
CLSD
– –
-10,433
Closed -$939K
CMPS
248
PUT
Compass Pathways
CMPS
$1.97B
– –
-1,131,400
Closed -$33.8M
COO icon
249
Cooper Companies
COO
$15B
– –
-160,000
Closed -$16.3M
CVAC
250
PUT
DELISTED
CureVac
CVAC
– –
-76,700
Closed -$4.19M
8 9
10
11 12

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Pura Vida Investments held 343 positions worth $2.76B, down 16% from $3.29B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments withdrew a net $439M in Q4 2021, closing 111 positions and reducing 100 holdings. Its most notable exit was Seer Inc, an estimated $24.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 33% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $15M.

  • Pura Vida Investments's largest Q4 2021 buy was BioMarin Pharmaceuticals: 170,210 shares worth $15M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2021, an estimated $17.9M increase.
  • Pura Vida Investments's biggest Q4 2021 reduction was LivaNova, cutting an estimated $20.2M.
  • Pura Vida Investments fully exited Seer Inc in Q4 2021, selling an estimated $24.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $2.76B portfolio in Q4 2021.
  • Pura Vida Investments opened 69 new positions and closed 111 in Q4 2021.
  • Pura Vida Investments's portfolio value fell 16% quarter-over-quarter to $2.76B.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.